List view / Grid view
Sean E. Harper is the Executive Vice President, Research and Development at Amgen. Dr. Harper joined Amgen in 2002 as vice president, Development, and has held several leadership roles, including heading the establishment of Amgen’s Medical Sciences capability, a translational medicine group focused on biomarker discovery, development, and integration into early phase clinical studies.
Dr. Harper served as vice president of Global Regulatory Affairs and Safety before assuming the role of senior vice president of Global Development and Corporate Chief Medical Officer. He became executive vice president, Research and Development in February 2012.
Prior to joining Amgen, Dr. Harper was senior director of clinical genomics at Merck Research Laboratories. He attended medical school at the University of California at San Francisco, completed internal medicine and gastroenterology training at the Massachusetts General Hospital, and was a postdoctoral fellow in the laboratory of Phillip A. Sharp at the Massachusetts Institute of Technology.
Amgen will present data evaluating Repatha® (evolocumab) at the upcoming…
23 August 2016 | By Amgen
Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome...
Amgen (NASDAQ:AMGN) has announced new data from three separate analyses…
Amgen (NASDAQ:AMGN) has announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication.
Phase 3 program underway to further assess Brodalumab as potential…
12 June 2014 | By Amgen
Phase 3 program underway to further assess Brodalumab as potential treatment for people living with psoriatic arthritis...
Study evaluating novel investigational IL-17 receptor antibody meets all primary…
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
Amgen announced top-line results from the primary overall survival analysis…
7 April 2014 | By Amgen
Amgen announced top-line results from the primary overall survival analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec...
Study meets primary endpoint of LDL cholesterol reduction First phase…
17 March 2014 | By Amgen
Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia - a rare and serious disease...
RUTHERFORD-2 study meets co-primary endpoints of ldl cholesterol reduction Amgen…
30 January 2014 | By Amgen
RUTHERFORD-2 study meets co-primary endpoints of ldl cholesterol reduction Amgen also announces results from phase 3 study with automated mini-doser completion of fifth phase 3 study forms basis for global filing plan...
Amgen announced that the Phase 3 LAPLACE-2 trial evaluating evolocumab…
28 January 2014 | By Amgen
Amgen announced that the Phase 3 LAPLACE-2 trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints...
Study meets co-primary endpoints of LDL cholesterol reduction...
23 January 2014 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
"The results of the study demonstrate significantly increased BMD and…
1 January 2014 | By Amgen
"The results of the study demonstrate significantly increased BMD and stimulation of bone formation with romosozumab treatment..."
Study meets co-primary endpoints of LDL cholesterol reduction...
17 December 2013 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
Data presented at American Heart Association Scientific sessions 2013 and…
20 November 2013 | By Amgen
Data presented at American Heart Association Scientific sessions 2013 and simultaneously published in circulation...
Differences in survival rates were pronounced in the subset of…
18 November 2013 | By Amgen
Differences in survival rates were pronounced in the subset of patients with stage IIIB, IIIC or IV M1a disease...
First long-term data of a PCSK9 Inhibitor to be featured…
14 November 2013 | By Amgen
First long-term data of a PCSK9 Inhibitor to be featured in clinical science: special reports session...
Prolia open-label extension trial showed continued increases in bone mineral…
4 October 2013 | By Amgen
Prolia open-label extension trial showed continued increases in bone mineral density and low fracture incidence for up to eight years...
